EU schizophrenia guidance highlights unmet needs
This article was originally published in Scrip
The European Medicines Agency's new guidelines on developing schizophrenia treatments now include recommendations on R&D that targets the condition's traditionally overlooked negative and cognitive symptoms. The guidelines are encouraging because they highlight areas of unmet need, but developmental challenges mean they will not "translate into the launch of marketed products in the mid-term", said Charlotte Mackey, a lead analyst at Datamonitor.
You may also be interested in...
Developing biosimilar orphan drugs is fraught with challenges and needs buy-in from regulators, developers, patients and clinicians.
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.